Geniposide attenuates mitochondrial dysfunction and memory deficits in APP/PS1 transgenic mice

Current Alzheimer Research

Volumn 11, Issue 6, 2014, Pages 580-587

  Lv, Cui ^a,b,c   Liu, Xiaoli ^a,b,c   Li, Zhi ^a,b,c   Liu, Hongjuan ^a,b,c   Chen, Tong ^d   Zhang, Wensheng ^a,b,c  

^a BEIJING NORMAL UNIVERSITY   (China)

^b Beijing Area Major Laboratory of Protection and Utilization of Traditional Chinese Medicine   (China)

^c BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^d KUNMING MEDICAL UNIVERSITY   (China)

Author keywords

Alzheimer's disease; APP PS1 transgenic mice; Cytochrome c oxidase; Geniposide; Mitochondrial dysfunction; Oxidative stress

Indexed keywords

CYTOCHROME C OXIDASE; GENIPOSIDE; MALONALDEHYDE; REACTIVE OXYGEN METABOLITE; AMYLOID PRECURSOR PROTEIN; APP PROTEIN, HUMAN; IRIDOID; NOOTROPIC AGENT; PRESENILIN 1; PSEN1 PROTEIN, HUMAN;

ALZHEIMER DISEASE; AMNESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN CORTEX; CONTROLLED STUDY; DISEASE COURSE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG EFFECT; ENZYME ACTIVITY; LEARNING; MALE; MEMORY; MEMORY CONSOLIDATION; MEMORY DISORDER; MITOCHONDRIAL MEMBRANE POTENTIAL; MORRIS WATER MAZE TEST; MOUSE; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; SPATIAL MEMORY; SWIMMING; ANIMAL; BRAIN; C57BL MOUSE; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; GENETICS; HUMAN; MAZE TEST; MEMORY DISORDERS; METABOLISM; MITOCHONDRION; PATHOPHYSIOLOGY; PHYSIOLOGY; RANDOMIZATION; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; ELECTRON TRANSPORT COMPLEX IV; HUMANS; IRIDOIDS; MALE; MALONDIALDEHYDE; MAZE LEARNING; MEMBRANE POTENTIAL, MITOCHONDRIAL; MEMORY DISORDERS; MICE, INBRED C57BL; MICE, TRANSGENIC; MITOCHONDRIA; NOOTROPIC AGENTS; OXIDATIVE STRESS; PRESENILIN-1; RANDOM ALLOCATION; REACTIVE OXYGEN SPECIES;

EID: 84904760940     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/1567205011666140618095925     Document Type: Article

References (45)

1. LaFerla FM, Green KN, Oddo S. Intracellular amyloid-beta in Alzheimer's disease. Nature reviews. Neurosci 8(7): 499-509 (2007).
2. Mattson MP. Pathways towards and away from Alzheimer's disease. Nature 430(7000): 631-639 (2004).
3. Reddy PH, Beal MF. Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease. Trend Mol Med 14(2): 45-53 (2008).
4. Zhang W, Bai M, Xi Y, Hao J, Liu L, Mao N, et al. Early memory deficits precede plaque deposition in APPswe/PS1dE9 mice: involvement of oxidative stress and cholinergic dysfunction. Free Radic Biol Med 52(8): 1443-1452 (2012).
5. Reddy PH. Mitochondrial oxidative damage in aging and Alzheimer's disease: implications for mitochondrially targeted antioxidant therapeutics. J Biomed Biotech 2006(3): 31372 (2006).
6. Carney JM. Oxidative stress leading to loss of critical proteases in Alzheimer's disease. An alternative view of the etiology of AD. Ann N Y Acad Sci 924: 160-163 (2000).
7. Smith MA, Rottkamp CA, Nunomura A, Raina AK, Perry G. Oxidative stress in Alzheimer's disease. Biochimica et biophysica acta 1502(1): 139-144 (2000).
8. Nunomura A, Perry G, Aliev G, Hirai K, Takeda A, Balraj EK, et al. Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol 60(8): 759-767 (2001).
9. Zhu X, Raina AK, Lee HG, Casadesus G, Smith MA, Perry G. Oxidative stress signalling in Alzheimer's disease. Brain Res 1000(1-2): 32-39 (2004).
10. Moreira PI, Nunomura A, Nakamura M, Takeda A, Shenk JC, Aliev G, et al. Nucleic acid oxidation in Alzheimer disease. Free Radic Biol Med 44(8): 1493-1505 (2008).
11. Pratico D, Clark CM, Liun F, Rokach J, Lee VY, Trojanowski JQ. Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease. Arch Neurol 59(6): 972-976 (2002).
12. Butterfield DA, Reed TT, Perluigi M, De Marco C, Coccia R, Keller JN, et al. Elevated levels of 3-nitrotyrosine in brain from subjects with amnestic mild cognitive impairment: implications for the role of nitration in the progression of Alzheimer's disease. Brain Res 1148: 243-248 (2007).
13. Butterfield DA, Lauderback CM. Lipid peroxidation and protein oxidation in Alzheimer's disease brain: potential causes and consequences involving amyloid beta-peptide-associated free radical oxidative stress. Free Radic Biol Med 32(11): 1050-1060 (2002).
14. Castellani R, Hirai K, Aliev G, Drew KL, Nunomura A, Takeda A, et al. Role of mitochondrial dysfunction in Alzheimer's disease. J Neurosci Res 70(3): 357-360 (2002).
15. Chen X, Stern D, Yan SD. Mitochondrial dysfunction and Alzheimer's disease. Curr Alzheimer Res 3(5): 515-520 (2006).
16. Wang X, Su B, Lee HG, Li X, Perry G, Smith MA, et al. Impaired balance of mitochondrial fission and fusion in Alzheimer's disease. J Neurosci 29(28): 9090-9103 (2009).
17. Reddy PH, McWeeney S, Park BS, Manczak M, Gutala RV, Partovi D, et al. Gene expression profiles of transcripts in amyloid precursor protein transgenic mice: up-regulation of mitochondrial metabolism and apoptotic genes is an early cellular change in Alzheimer's disease. Hum Mol Genet 13(12): 1225-1240 (2004).
18. Reddy PH. Amyloid precursor protein-mediated free radicals and oxidative damage: implications for the development and progression of Alzheimer's disease. J Neurochem 96(1): 1-13 (2006).
19. Calkins MJ, Manczak M, Mao P, Shirendeb U, Reddy PH. Impaired mitochondrial biogenesis, defective axonal transport of mitochondria, abnormal mitochondrial dynamics and synaptic degeneration in a mouse model of Alzheimer's disease. Hum Mol Genet 20(23): 4515-4529 (2011).
20. Manczak M, Calkins MJ, Reddy PH. Impaired mitochondrial dynamics and abnormal interaction of amyloid beta with mitochondrial protein Drp1 in neurons from patients with Alzheimer's disease: implications for neuronal damage. Hum Mol Genet 20(13): 2495-2509 (2011).
21. de la Monte SM, Wands JR. Molecular indices of oxidative stress and mitochondrial dysfunction occur early and often progress with severity of Alzheimer's disease. J Alzheimer's Dis 9(2): 167-181 (2006).
22. Lee HP, Pancholi N, Esposito L, Previll LA, Wang X, Zhu X, et al. Early induction of oxidative stress in mouse model of Alzheimer disease with reduced mitochondrial superoxide dismutase activity. PloS one 7(1): e28033 (2012).
23. Koo HJ, Lim KH, Jung HJ, Park EH. Anti-inflammatory evaluation of gardenia extract, geniposide and genipin. J Ethnopharmacol 103(3): 496-500 (2006).
24. Liu J, Yin F, Zheng X, Jing J, Hu Y. Geniposide, a novel agonist for GLP-1 receptor, prevents PC12 cells from oxidative damage via MAP kinase pathway. Neurochem Intern 51(6-7): 361-369 (2007).
25. Peng CH, Huang CN, Hsu SP, Wang CJ. Penta-acetyl geniposideinduced apoptosis involving transcription of NGF/p75 via MAPKmediated AP-1 activation in C6 glioma cells. Toxicology 238(2-3): 130-139 (2007).
26. Liu J, Zhang Y, Deng X, Yin F. Geniposide decreases the level of Abeta1-42 in the hippocampus of streptozotocin-induced diabetic rats. Acta biochimica et biophysica Sinica 45(9): 787-791 (2013).
27. Clark JD, Gebhart GF, Gonder JC, Keeling ME, Kohn DF. Special Report: The 1996 Guide for the Care and Use of Laboratory Animals. ILAR journal / National Research Council, Institute of Laboratory Animal Resources. 38(1): 41-48 (1997).
28. Vorhees CV, Williams MT. Morris water maze: procedures for assessing spatial and related forms of learning and memory. Nature protocols 1(2): 848-858 (2006).
29. Li X, Lv Y, Yu S, Zhao H, Yao L. The effect of cadmium on Abeta levels in APP/PS1 transgenic mice. Exp Ther Med 4(1): 125-130 (2012).
30. Huang T, Fang F, Chen L, Zhu Y, Zhang J, Chen X, et al. Ginsenoside Rg1 attenuates oligomeric Abeta(1-42)-induced mitochondrial dysfunction. Curr Alzheimer Res 9(3): 388-395 (2012).
31. Emaus RK, Grunwald R, Lemasters JJ. Rhodamine 123 as a probe of transmembrane potential in isolated rat-liver mitochondria: spectral and metabolic properties. Biochimica et biophysica acta 850(3): 436-448 (1986).
32. Chen J, Liao W, Gao W, Huang J, Gao Y. Intermittent hypoxia protects cerebral mitochondrial function from calcium overload. Acta neurologica Belgica 113(4): 507-513 (2013).
33. Scaduto RC, Jr., Grotyohann LW. Measurement of mitochondrial membrane potential using fluorescent rhodamine derivatives. Biophys J 76(1 Pt 1): 469-477 (1999).
34. Kawas CH, Corrada MM. Alzheimer's and dementia in the oldestold: a century of challenges. Curr Alzheimer Res 3(5): 411-419 (2006).
35. Dodart JC, Meziane H, Mathis C, Bales KR, Paul SM, Ungerer A. Behavioral disturbances in transgenic mice overexpressing the V717F beta-amyloid precursor protein. Behav Neurosci 113(5): 982-990 (1999).
36. Koistinaho M, Ort M, Cimadevilla JM, Vondrous R, Cordell B, Koistinaho J, et al. Specific spatial learning deficits become severe with age in beta-amyloid precursor protein transgenic mice that harbor diffuse beta-amyloid deposits but do not form plaques. Proc Natl Acad Sci USA 98(25): 14675-14680 (2001).
37. King DL, Arendash GW, Crawford F, Sterk T, Menendez J, Mullan MJ. Progressive and gender-dependent cognitive impairment in the APP(SW) transgenic mouse model for Alzheimer's disease. Behav Brain Res 103(2): 145-162 (1999).
38. Knobloch M, Konietzko U, Krebs DC, Nitsch RM. Intracellular Abeta and cognitive deficits precede beta-amyloid deposition in transgenic arcAbeta mice. Neurobiol Aging 28(9): 1297-1306 (2007).
39. Sonnen JA, Breitner JC, Lovell MA, Markesbery WR, Quinn JF, Montine TJ. Free radical-mediated damage to brain in Alzheimer's disease and its transgenic mouse models. Free Radic Biol Med 45(3): 219-230 (2008).
40. Keller JN, Schmitt FA, Scheff SW, Ding Q, Chen Q, Butterfield DA, et al. Evidence of increased oxidative damage in subjects with mild cognitive impairment. Neurology 64(7): 1152-1156 (2005).
41. Bonardi C, de Pulford F, Jennings D, Pardon MC. A detailed analysis of the early context extinction deficits seen in APPswe/PS1dE9 female mice and their relevance to preclinical Alzheimer's disease. Behav Brain Res 222(1): 89-97 (2011).
42. Ikonomidou C, Kaindl AM. Neuronal death and oxidative stress in the developing brain. Antioxid Redox Signal 14(8): 1535-1550 (2011).
43. Cardoso SM, Proenca MT, Santos S, Santana I, Oliveira CR. Cytochrome c oxidase is decreased in Alzheimer's disease platelets. Neurobiol Aging 25(1): 105-110 (2004).
44. Du H, Guo L, Yan S, Sosunov AA, McKhann GM, Yan SS. Early deficits in synaptic mitochondria in an Alzheimer's disease mouse model. Proc Natl Acad Sci USA 107(43): 18670-18675 (2010).
45. Tanaka N, Goto Y, Akanuma J, Kato M, Kinoshita T, Yamashita F, et al. Mitochondrial DNA variants in a Japanese population of patients with Alzheimer's disease. Mitochondrion 10(1): 32-37 (2010).